Close Menu

NEW YORK – Autoimmune diagnostic firm Exagen announced Wednesday it has entered an exclusive worldwide license agreement with the Ohio State Innovation Foundation to develop and market a fibromyalgia blood test.

The rule-in test, developed by researchers at The Ohio State University, uses vibrational spectroscopy and metabolomic analysis to differentiate patients with fibromyalgia from other disorders, such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, or chronic lower back pain. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.